These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39236755)

  • 21. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
    Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
    Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
    Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
    Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
    Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS; Sigal D
    Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Jones KA; Bossler AD; Bellizzi AM; Snow AN
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 30. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.
    König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H
    Pharmacology; 2022; 107(7-8):433-438. PubMed ID: 35526519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M; Rodrigues M
    Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract]   [Full Text] [Related]  

  • 33. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
    Garrido P; Hladun R; de Álava E; Álvarez R; Bautista F; López-Ríos F; Colomer R; Rojo F
    Clin Transl Oncol; 2021 Aug; 23(8):1529-1541. PubMed ID: 33620682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
    Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
    J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
    Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
    Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory infantile high-grade glioma containing TRK-fusion responds to larotrectinib.
    Waters TW; Moore SA; Sato Y; Dlouhy BJ; Sato M
    Pediatr Blood Cancer; 2021 May; 68(5):e28868. PubMed ID: 33403813
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular characterization of cancers with NTRK gene fusions.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.